We have located links that may give you full text access.
Journal Article
Meta-Analysis
Systematic Review
Docosahexaenoic acid and bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis.
BACKGROUND: Bronchopulmonary dysplasia (BPD) is a common and serious complication of extremely preterm birth. Given the anti-inflammatory properties, docosahexaenoic acid (DHA) supplementation has been proposed as a strategy for the management of BPD. This study aimed to investigate the effects of DHA supplementation on BPD based on a systematic review.
METHODS: A comprehensive literature search was conducted using ClinicalTrials.Gov, CINAHL, Cochrane Library, EMBASE, MEDLINE, PubMed, and the WHO ICTRP from their respective dates of inception to June 2017. The studies included were randomized controlled trials (RCTs) that enrolled preterm infants <33 weeks of gestational age. Trials were included if DHA supplementation was compared with a control.
RESULTS: Four RCTs from five reports (1,966 neonates) met our inclusion criteria. The meta-analysis of these studies showed that DHA supplementation did not decrease the risk of BPD at 36 weeks of postmenstrual age among preterm infants ( low certainty of evidence ). DHA supplementation did not significantly reduce the risk of other neonatal morbidities including death ( low certainty of evidence ), BPD at 28 days of life ( moderate certainty of evidence ), necrotizing enterocolitis ( low certainty of evidence ), intraventricular hemorrhage, severe retinopathy of prematurity, or sepsis.
CONCLUSION: DHA supplementation may not exert significant clinical benefits in the treatment of BPD and other neonatal morbidities.
METHODS: A comprehensive literature search was conducted using ClinicalTrials.Gov, CINAHL, Cochrane Library, EMBASE, MEDLINE, PubMed, and the WHO ICTRP from their respective dates of inception to June 2017. The studies included were randomized controlled trials (RCTs) that enrolled preterm infants <33 weeks of gestational age. Trials were included if DHA supplementation was compared with a control.
RESULTS: Four RCTs from five reports (1,966 neonates) met our inclusion criteria. The meta-analysis of these studies showed that DHA supplementation did not decrease the risk of BPD at 36 weeks of postmenstrual age among preterm infants ( low certainty of evidence ). DHA supplementation did not significantly reduce the risk of other neonatal morbidities including death ( low certainty of evidence ), BPD at 28 days of life ( moderate certainty of evidence ), necrotizing enterocolitis ( low certainty of evidence ), intraventricular hemorrhage, severe retinopathy of prematurity, or sepsis.
CONCLUSION: DHA supplementation may not exert significant clinical benefits in the treatment of BPD and other neonatal morbidities.
Full text links
Related Resources
Trending Papers
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app